# Validation of the Oncoliq Test for the Early Detection of Breast Cancer.

> **NCT07331506** · — · RECRUITING · sponsor: **Oncoliq US Inc** · enrollment: 300 (estimated)

## Conditions studied

- Breast Cancer Detection
- Breast Cancer Early Stage Breast Cancer (Stage 1-3)
- Breast Cancer Female
- Breast Cancer - Ductal Carcinoma in Situ (DCIS)
- Breast Cancer - Infiltrating Ductal Carcinoma
- Breast Cancer With Low to Intermediate HER2 Expression
- Breast Cancer (Early Breast Cancer)
- Breast Cancer - Female

## Interventions

- **OTHER:** Peripheral blood draw

## Key facts

- **NCT ID:** NCT07331506
- **Lead sponsor:** Oncoliq US Inc
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2025-10-17
- **Primary completion:** 2026-02-28
- **Final completion:** 2026-02-28
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2026-01-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331506

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331506, "Validation of the Oncoliq Test for the Early Detection of Breast Cancer.". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT07331506. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*